First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer

被引：0

作者：

Saura, Cristina

Sanz, Lucia

Kim, Janice

Jhaveri, Komal L.

Guerrero, Angel

Ortega, Pablo Tolosa

Schott, Anne F.

Curigliano, Giuseppe

Perez, Cesar Augusto

Nanda, Rita

Hamilton, Erika P.

Henry, Jason Timothy

Wisinski, Kari Braun

Sammons, Sarah L.

Segar, Jennifer Margaret

Aix, Santiago Ponce

Sirven, Milana Bergamino

Spira, Alexander I.

Schram, Alison M.

Varkaris, Andreas

机构：

[1] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol, Barcelona, Spain

[2] Vall Hebron, Barcelona, Spain

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Inst Valenciano Oncol, Valencia, Spain

[6] GEICAM Breast Canc Grp, Valencia, Spain

[7] 12 Octubre Univ Hosp, Madrid, Spain

[8] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[9] Ist Europeo Oncol, Milan, Italy

[10] IRCCS, Milan, Italy

[11] Univ Milan, Milan, Italy

[12] Florida Canc Specialists, Sarah Cannon Res Inst, Orlando, FL USA

[13] Univ Chicago Med, Chicago, IL USA

[14] Sarah Cannon Res Inst, Nashville, TN USA

[15] HealthONE, Sarah Cannon Res Inst, Denver, CO USA

[16] Carbone Canc Ctr, Madison, WI USA

[17] Dana Farber Canc Inst, Boston, MA USA

[18] Univ Arizona Canc Ctr, Tucson, AZ USA

[19] Gustave Roussy Canc Ctr, Villejuif, France

[20] Catalan Inst Oncol ICO, Dept Med Oncol, Badalona, Spain

[21] B ARGO Badalona Appl Res Grp Oncol, Barcelona, Spain

[22] Univ Autonoma Barcelona, IGTP Hlth Res Inst Germans Trias & Pujol, Barcelona, Spain

[23] Virginia Canc Specialists, NEXT Oncol, Fairfax, VA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS1128

引用

页数：1

共 50 条

[1] First-in-human global multi-center study of RLY-2608, a pan-mutant and isoform-selective PI3Kα inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer
Perez, Cesar Augusto
Henry, Jason Timothy
Varkaris, Andreas
Subbiah, Vivek
Spira, Alexander I.
Schmidt, Oleg
Shen, Jinshan
Guo, Wei
Hunter, Tamieka
Jen, Kai Yu
Padval, Mahesh
Karanovic, Djuro
Wolf, Beni B.
Hamilton, Erika P.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] First-in-human global multi-center study of RLY-2608, a pan mutant and isoform selective PI3Kα inhibitor, as a single agent in advanced solid tumor patients and in combination with fulvestrant in patients with advanced breast cancer
Varkaris, Andreas
Hamilton, Erika
Henry, Jason
Spira, Alexander I.
Schram, Alison M.
McGuinness, Julia E.
Tan, Gege
Li, Xiaoyan
Hunter, Tamieka
Samadani, Ramin
Timm, Alison
Karanovic, Djuro
Subbiah, Vivek
Perez, Cesar A.
[J]. CANCER RESEARCH, 2023, 83 (05)
[3] First-in-human global study of RLY-2608, a panmutant and isoform selective PI3Ka inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer
Varkaris, Andreas
Jhaveri, Komal
Cabanas, Elena Garralda
Sanz, Lucia
Kim, Janice
Perez, Cesar A.
Hamilton, Erika
Spira, Alexander I.
Wisinski, Kari
Guerrero, Angel
Henry, Jason
Ahnert, Jordi Rodon
Tan, Gege
Li, Xiaoyan
Hummel, Diana
Hunter, Tamieka
Timm, Alison
Samadani, Ramin
Puente-Poushnejad, Erika
Kwak, Eunice
Mar, Brenton G.
Schram, Alison M.
[J]. CANCER RESEARCH, 2024, 84 (09)
[4] Discovery and characterization of RLY-2608: The first allosteric, mutant, and isoform-selective inhibitor of PI3Kα
Pazolli, Ermira
Kipp, Randy
Boezio, Alessandro
Gunaydin, Hakan
Iskandar, Amanda
Zubrowski, Matthew
Williams, Bret
Shortsleeves, Kelley
Larivee, Alexandre
McLean, Tom
Michelsen, Klaus
Zeng, Hongtao
LaRochelle, Jonathan
Manna, Joe
DiPietro, Lucian
Mader, Mary
Bennet, Bindu
Wilbur, Jeremy
Wang, Qi
Pierce, Levi
Martin, Iain
Watters, James
Fortin, Pascal
Bergstrom, Donald
[J]. MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[5] RLY-2608: The first allosteric mutant- and isoform-selective inhibitor of PI3Kα, is efficacious as a single agent and drives regressions in combination with standard of care therapies in PIK3CA mutant breast cancer models
Pazolli, Ermira
Kipp, Randy
Boezio, Alessandro
Gunaydin, Hakan
Iskandar, Amanda
Zubrowski, Matthew
Williams, Bret
Shortsleeves, Kelley
Larivee, Alexandre
McLean, Tom
Michelsen, Klaus
Zeng, Hongtao
LaRochelle, Jonathan
Manna, Joe
DiPietro, Lucian
Lescarbeau, Andre
Mader, Mary
Bennet, Bindu
Wilbur, Jeremy
Wang, Qi
Pierce, Levi
Martin, Iain
Watters, James
Fortin, Pascal
Bergstrom, Donald
[J]. CANCER RESEARCH, 2022, 82 (04)
[6] First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors
Burris, H.
Rodon, J.
Sharma, S.
Herbst, R. S.
Tabernero, J.
Infante, J. R.
Silva, A.
Demanse, D.
Hackl, W.
Baselga, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[7] A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors
Baselga, J.
De Jonge, M. J.
Rodon, J.
Burris, H. A., III
Birle, D. C.
De Buck, S. S.
Demanse, D.
Ru, Q. C.
Goldbrunner, M.
Bendell, J. C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[8] First-in-human, phase I, dose-escalation study of selective PI3Kα isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.
Juric, Dejan
De Bono, Johann Sebastian
LoRusso, Patricia
Nemunaitis, John J.
Heath, Elisabeth I.
Kwak, Eunice Lee
Macarulla, Teresa
Geuna, Elena
Luken, Maria Jose de Miguel
Patel, Chirag
Kuida, Keisuke
Sankoh, Serap
Zohren, Fabian
Shou, Yaping
Tabernero, Josep
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients With Advanced Solid Tumors
Bedard, Philippe L.
Davies, Michael A.
Kopetz, Scott
Juric, Dejan
Shapiro, Geoffrey I.
Luke, Jason J.
Spreafico, Anna
Wu, Bin
Castell, Christelle
Gomez, Corinne
Cartot-Cotton, Sylvaine
Mazuir, Florent
Dubar, Michel
Micallef, Sandrine
Demers, Brigitte
Flaherty, Keith T.
[J]. CANCER, 2018, 124 (02) : 315 - 324
[10] First-in-human study of AMG 337, a highly selective oral inhibitor of MET, in adult patients (pts) with advanced solid tumors
Hong, David S.
LoRusso, Patricia
Hamid, Omid
Beaupre, Darrin M.
Janku, Filip
Khan, Rabla
Kittaneh, Mualad
Loberg, Robert D.
Amore, Benny
Caudillo, Isaac
Hwang, Yuying C.
Tang, Rui
Mgarmchamnanrith, Gataree
Kwak, Eunice Leo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

← 1 2 3 4 5 →